Dear Colleagues --
I attach a December 8 New York Times article titled, "Supplements Claiming to Ease Opioid Addiction Come Under Scrutiny." You can read it here.
As the article notes, there is growing concern among regulators, non-profit organizations, and the medical community over the growth of alleged opioid addiction treatment products -- some sold as dietary supplements. The primary ingredient in such products is kratom. Recently FDA Commissioner, Scott Gottlieb, issued a consumer alert on this very subject, found here, underscoring FDA's concern with respect to safety, misuse, and regulatory status of kratom.
On April 30, 2014, UNPA issued a "no-sale of kratom as a condition of membership" policy, and we remind our members this policy remains in full effect. To our knowledge, no UNPA member sells kratom, and we request that all members observe this policy. We believe the public debate over the regulatory status of the use of kratom is far from over and remain concerned that our core principles underlying the use of dietary supplements -- safety, science & quality -- not be compromised as a result of the kratom debate.